SNMMI Consensus Statement on Patient Selection and Appropriate Use of ¹⁷⁷Lu-PSMA-617 Radionuclide Therapy.

IF 9.1 1区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Journal of Nuclear Medicine Pub Date : 2023-09-01 Epub Date: 2023-06-08 DOI:10.2967/jnumed.123.265952

Thomas A Hope, Emmanuel S Antonarakis, Lisa Bodei, Jeremie Calais, Amir Iravani, Heather Jacene, Phillip J Koo, Alicia K Morgans, Joseph R Osborne, Scott T Tagawa, Mary-Ellen Taplin, Oliver Sartor, Michael J Morris

引用次数: 0

查看原文本刊更多论文

SNMMI关于患者选择和适当使用177Lu-PSMA-617放射性核素治疗的共识声明。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Nuclear Medicine 医学-核医学

CiteScore

13.00

自引率

8.60%

发文量

340

审稿时长

1 months

期刊介绍： The Journal of Nuclear Medicine (JNM), self-published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), provides readers worldwide with clinical and basic science investigations, continuing education articles, reviews, employment opportunities, and updates on practice and research. In the 2022 Journal Citation Reports (released in June 2023), JNM ranked sixth in impact among 203 medical journals worldwide in the radiology, nuclear medicine, and medical imaging category.

SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy.

SNMMI Consensus Statement on Patient Selection and Appropriate Use of ¹⁷⁷Lu-PSMA-617 Radionuclide Therapy.